Partner Susan Natland was quoted in “Chaos is a Ladder for the Startup Lawyer,” which was published in Orange County Lawyer Magazine. Excerpt: “Securing trademark and patent assets and other IP assets…
Partner Kerry Taylor was quoted in, “More Federal Circuit Judges Question PTAB Appointment Ruling (1),” an article published by Bloomberg Law. Excerpt: “While not all judges may be entirely on board with Arthrex,…
Partner Tom Cowan twitter post was featured in “Users Lament PAIR Changes During USPTO Forum,” an article published by IP Watchdog Excerpt: Currently, if using Private PAIR, you can only see the apps associated…
Knobbe Martens is pleased to announce that 19 partners have been recognized as 2020 Southern California “Super Lawyers”. The prestigious ranking, achieved by just five percent of attorneys in the…
Partner John Sganga was quoted in “New Evidence Precedent Gives Lawyers a Patent Board Road Map,” an article published by Bloomberg Law Excerpt: Attorneys may face better odds when trying to convince Patent…
Partner Joseph Re was quoted in “Justices Slam Door On Pleas To Redo Patent Eligibility,” an article published by Law360 Excerpt: The chances of the U.S. Supreme Court altering patent eligibility standards anytime…
Partner Philip Nelson was quoted in “How A Pro-Software Patent Bill Could Affect The Medtech Industry,” an article published by Medtech Insight Excerpt: Though it didn’t even get to committee, a bill…
Partner Steve Jensen was quoted in “Apple Hit With IP Suit Over Watch’s Health Data Tracking Tech,” an article published by Law360 Excerpt: “Masimo has a history of protecting its innovations when necessary,”…
Knobbe Martens, one of the leading intellectual property law firms in the United States, is pleased to announce that eight associates have been promoted to partner effective January 1, 2020. …
Partner Gerard Von Hoffmann was quoted in “Protecting IP Should Remain a Critical Part of Medtech Business Strategy,” an article published by MedTech Intelligence Excerpt: Medical device companies continue to value patents as…
